Interim statement on covid-19 vaccine booster doses

References:

1. 1.↵
   1. Khoury DS,
   2. Cromer D,
   3. Reynaldi A,
   4. Schlub TE,
   5. Wheatley AK,
   6. Juno JA et al.

   Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. 2021;27:1205–11. doi: 10.1038/s41591-021-01377-8.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Emary KRW,
   2. Golubchik T,
   3. Aley PK,
   4. Ariani CV,
   5. Angus B,
   6. Bibi S et al.

   Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351–62.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Widge AT,
   2. Rouphael NG,
   3. Jackson LA,
   4. Anderson EJ,
   5. Roberts PC,
   6. Makhene M et al.

   Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2021;384:80–2. doi: 10.1056/NEJMc2032195.

   OpenUrlPubMed
4. 4.↵
   1. Whitaker H,
   2. Tsang R,
   3. Byford R,
   4. Andrews N,
   5. Sherlock J,
   6. Pillai S et al.

   Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. 2021.
5. 5.↵
   1. Bergwerk M,
   2. Gonen T,
   3. Lustig Y,
   4. Amit S,
   5. Lipsitch M,
   6. Cohen C et al.

   Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. New England Journal of Medicine. 2021. doi: 10.1056/NEJMoa2109072.